Latest Holista Colltech (ASX:HCT) News

Holista Colltech has agreed to pay US$1.8 million to settle a US judgment enforced by the Supreme Court of Western Australia, resolving a long-running dispute with ProImmune Company LLC. The settlement reflects a significant discount on the original US$2.06 million judgment plus accruing interest and legal fees.

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.

Holista Colltech’s shares remain suspended on the ASX following a trading halt linked to ongoing legal issues with ProImmune Company LLC, with no resolution in sight.

Holista Colltech has reported a positive operating cash flow for the December quarter, driven by disciplined cost management and a successful capital raise, despite softer sales and ongoing legal disputes.

Holista Colltech has received a formal notice from ASIC seeking recovery of approximately $1.09 million in legal costs related to Federal Court proceedings. The company is currently reviewing its options amid ongoing regulatory scrutiny.

Holista Colltech reported improved cash flow management and robust growth in its dietary supplements division for 3QFY25, while navigating ongoing legal challenges with ProImmune.

Holista Colltech has raised $2.295 million through a share placement to two international investors, aiming to bolster its operations and balance sheet. The move highlights the company’s ongoing efforts to support growth across its health and wellness divisions.

Holista Colltech reports a sharp 70% reduction in net loss and an 8.6% revenue rise, driven by strong supplements sales and a landmark collagen partnership with Regenerex Pharma.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Holista Colltech reported steady customer receipts and a 38% surge in dietary supplement sales for 2QFY25, while progressing its high-value nano-collagen business and refreshing its leadership team.

Holista Colltech has confirmed Leong Man Loong as its permanent CEO, cementing leadership stability during a pivotal recovery phase. His symbolic $1 salary underscores a commitment to long-term growth.

Holista Colltech Limited has responded to an ASX price query regarding recent unusual trading activity, confirming no undisclosed material information exists to explain the surge.